Stop Pills That Kill Act

H.R. 1800, Solidify Iran Sanctions Act (SISA), all provisions. H.R. 3447, Chip Security Act, all provisions. H.R. 5334, Lindsey O. Graham Sanctioning Russia and Iran Act of 2026, all provisions. H.R. 5853, ECRA Statute of Limitations Extension, all provisions. H.R. 6275, China AI Power Report Act, all provisions. H.R. 6331, Addressing Dangerous Vulnerabilities in Exports and Research to Strategic Adversaries, Regimes, and Industrial Entities of Security Concern (ADVERSARIES) Act, all provisions. H.R. 6875, AI OVERWATCH Act, all provisions. H.R. 7003, BIS Strategic Talent Recruitment to Enhance National Guardrails for Technological Handling (STRENGTH) Act, all provisions. H.R. 7184, Preventing Rogue Equipment for Synthetic Substances (PRESS) Act, all provisions. H.R. 8005, Stop Pills That Kill Act, all provisions. H.R. 8170, Multilateral Alignment of Technology Controls on Hardware (MATCH) Act, all provisions. H.R. 9450, Countering Russian Trafficking Act, all provisions. H.R. 9721, Fiscal Sponsorship Transparency Act of 2026, all provisions. H.R. 9764, Hindering Oppressive Nations from Obtaining Revenue Act, all provisions. H.R. 9772, Foreign Funding Transparency Act, all provisions. H.R. 9982, Polisario Front Terrorist Designation Act of 2026, all provisions. H.R. 10076, Lindsey O. Graham Sanctioning Russia and Iran Act of 2026, all provisions. S. 1259, Manifest Modernization Act, all provisions. S. 1705, Chip Security Act, all provisions. S. 1889, Solidify Iran Sanctions Act (SISA), all provisions. S. 2904, Sanctioning Harborers And Dodgers Of Western (SHADOW) Sanctions Act of 2026, all provisions. S. 4281, Multilateral Alignment of Technology Controls on Hardware (MATCH) Act, all provisions. S. 4456, AI OVERWATCH Act, all provisions. S. 5025, Lindsey O. Graham Sanctioning Russia Act of 2026, all provisions. S. 5083, Fiscal Sponsorship Transparency Act of 2026, all provisions. S. 5252, Blocking Large-scale Adversarial Distillation Efforts Act of 2026, all provisions. S. 5356, Lebanon Sanctions, Stabilization, and Support Act, all provisions. S. 5379, BIS Strategic Talent Recruitment to Enhance National Guardrails for Technological Handling (STRENGTH) Act, all provisions. S. 5380, ECRA Statute of Limitations Extension, all provisions. S. 5381, Addressing Dangerous Vulnerabilities in Exports and Research to Strategic Adversaries, Regimes, and Industrial Entities of Security Concern (ADVERSARIES) Act, all provisions. S. 5382, China AI Power Report Act, all provisions. S. 5551, Developing Overseas Mineral Investments and New Allied Networks for Critical Energies (DOMINANCE) Act, all provisions. Issues Related to Anti-Money Laundering and Combating the Financing of Terrorism; Captagon, Fentanyl, and International Narcotics Production and Trafficking; Evaluating Sanctions, Export Controls, and AML Regulations, Regulatory Authorities, and Legislative Authorities; Foreign Boycotts of Israel; Foreign Investment in Latin America; Hamas Smuggling Tunnels, Financial Assets, and Funding Streams; IEEPA Reform; Implementation and Oversight of the Countering Americas Adversaries Through Sanctions Act (CAATSA); Iranian Oil Sanctions Enforcement; Monitoring Emerging Economic Security Risks; Muslim Brotherhood Funding Streams; National Security-Related Foreign Investment Screening Processes for U.S. Allies; Non-Western Payment and Messaging Systems; U.S. Adversaries Illicit Finance Activities; U.S. Adversaries Sanctions Evasion Schemes; U.S. China Sanctions Policy; U.S. Corruption Sanctions Policy; U.S. Counter-Kleptocracy Strategy; U.S. Cuba Sanctions Policy; U.S. Digital Assets Policy; U.S. Economic Statecraft Policy; U.S. Export Control Policy; U.S. Hezbollah Sanctions Policy; U.S. Investment Screening and Security; U.S. Iran Sanctions Policy; U.S. Muslim Brotherhood Sanctions Policy; U.S. North Korea Sanctions Policy; U.S. Russia Oil Waivers and Sanctions Policy; U.S. Sanctions Authorities, Implementation, Enforcement, Resourcing, and Policy; U.S. Terror Finance Policy; and U.S. Turkey Sanctions Policy (no bill).

Client expense: $210,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Cannabis Administration and Opportunity Act (CAOA) (S. 5022); Cashless Bail Reporting Act (H.R. 5625); Combating Illicit Xylazine Act (S. 545/H.R. 1266); Combating Organized Retail Crime Act (CORCA) (S. 1404/H.R. 2853); Continuing Appropriations / temporary funding extension (H.R. 6500); District of Columbia Cash Bail Reform Act (S. 2706/H.R. 5214); Federal Carjacking Enforcement Act (S. 1572/H.R. 6155); James T. Woods Act (H.R. 6719); Kayleigh's Law (S. 5372/H.R. 8481); National Defense Authorization Act (NDAA) (S. 4784/H.R. 8800); No Bailouts Act (H.R. 8821); STOP CSAM Act (S. 1829); STOP Nitazenes Act (H.R. 7970); Stop Pills That Kill Act (S. 3087/H.R. 8005); Right to Trial Act (H.R. 9095); Prohibiting Punishment of Acquitted Conduct Act (S. 3483); 702 reauthorization

Client expense: $15,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Justice, Dept of (DOJ), SENATE

Tracking -a federal district court vacated a Health Resources and Services Administration (HRSA) policy restricting 340B disproportionate share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. share hospitals (DSHs) from using group purchasing organizations (GPOs) alongside replenishment models for outpatient drugs, concluding the agency failed to provide adequate justification under the Administrative Procedure Act. Tracking Bills - S. 3206 Transgender Health Care Access Act, S. 2709 and HR 5081 Telehealth Modernization Act, HR 6468 Rural Residency Placement & Development Act of 2025 - the area is challenged with med students match with this region which challenges the ability to recruit new health care professionals to remain in the area. HR5821 - Rural Hospital Fairness Act, S891 - Bipartisan Health Act, S526 PBM Transparency Act - provides for full transparency in drug pricing to ensure any savings go back to patients - the Federal Trade Commission will complete a 6(b) study examining the effects of consolidation on pricing in the PBM industry, as well as other potentially abusive behavior by PBMs. The bill instructs the FTC to provide policy recommendations to Congress to improve competition and protect consumers. The hospital supports any mechanism for drug price transparency for patients. S527 - Prescription Pricing for People Act of 2025 - A study by FTC to study role of intermediaries (PBMs) in pharm. supply chain and provide recommendations for improvement of costs to patients. S927 Protecing Pharmacies in Medicaid Act - PBMs charge Medicaid more than they pay pharmacies for a particular drug, increases corporate profits while driving up costs for Medicaid. PBMs use of spread pricing has also been linked to the increasing failure rate for independent pharmacies, which provide a critical source of health care and community for rural communities. HR267 Health Care Transparency Act - statutory authority for requirements for hospitals and health insurance plans to disclose certain information about the costs for items and services. We need to ensure requirements are within appropriate information to be disclosed - challenged with varied reimbursement rates. HR 2214 - DRUG Act. The bill is impacting prescription drug costs, access, and manufacturing practices. These include the Inflation Reduction Act's provisions for Medicare Part D, amendments to the Federal Sentencing Guidelines, and potential changes related to PBMs and direct-to-consumer advertising. Supporting best and most affordable care for patients. Tracking House Bills on price transaparency, drug controls, community care H.R. 9393 - Lower Costs, More Transparency Act of 2026 (Guthrie, Pallone): Codifies existing price transparency rules for hospitals and health plans American Hospital Association. H.R. 9390 - Prices on the Wall Act of 2026 (Miller-Meeks): Requires hospitals to post service pricing physically on their walls American Hospital Association. H.R. 9397 - Premium Transparency Act (Pfluger, Moran): Mandates insurers to disclose how much of premiums go toward healthcare costs subscriber.politicopro.com. H.R. 9396 - Prior Authorization Accountability Act (Goldman-TX): Improves transparency and consistency in prior authorization for Medicare Advantage plans American Hospital Association. H.R. 5243 - Medicare Advantage Data Transparency Amendment: Increases data transparency for supplemental benefits under Medicare Advantage House Committee on Energy and Commerce. H.R. 9395 - Transparency in Medicare Advantage Steering Act (Ocasio-Cortez): Enhances oversight and transparency in Medicare Advantage steering House Committee on Energy and Commerce. Access to Care & Community Health H.R. 8201 - Expanding Community Access to Health Services Act (Lee-NV): Requires community health centers to provide behavioral health and substance use disorder services, with related funding AACOM. H.R. 9389 - Nutrition Education and Chronic Disease Prevention in Community Health Centers Act of 2026 (Harshbarger): Expands nutrition education and chronic disease prevention services at Federally Qualified Health Centers AACOM. H.R. 3514 - Improving Seniors Timely Access to Care Act of 2025 (Kelly, DelBene): Reduces variation in prior authorization methods for Medicare Advantage plans American Hospital Association. Illicit Drug Control H.R. 1266 - Combatting Illicit Xylazine Act (Panetta, Pfluger): Places xylazine on the controlled substances list subscriber.politicopro.com. H.R. 7970 - STOP Nitazenes Act (Latta): Places nitazenes on the controlled substances list subscriber.politicopro.com. H.R. 2004 - Tylers Law (Lieu, Latta): Expands naloxone access and overdose prevention measures House Committee on Energy and Commerce. H.R. 1561 - ALERT Communities Act (Crockett, Gooden): Supports community-based overdose prevention and response House Committee on Energy and Commerce. H.R. 7994 - HERO Act (Ruiz): Enhances harm reduction and overdose prevention services House Committee on Energy and Commerce. H.R. 5880 - Fight Illicit Pill Presses Act (Hageman, Stansbury) & H.R. 8005 - Stop Pills That Kill Act (Evans): Target illicit drug manufacturing and distribution House Committee on Energy and Commerce. H.R. 7184 - PRESS Act (McDowell): Addresses illicit drug production and distribution

Client expense: Not reported · Firm income: $24,000

Government targets: HOUSE OF REPRESENTATIVES, Health Resources & Services Administration (HRSA), SENATE